Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ABCC9 | O60706 | 5/20 | 0.42 |
| ▸ | ABCC8 | Q09428 | 5/20 | 0.42 |
| ▸ | KCNJ11 | Q14654 | 5/20 | 0.42 |
| ▸ | KCNJ8 | Q15842 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847991 | 0.80 | MAPT (0.70) | MAPTALDH1A1LMNAMAPK1TP53 | |
| SCHEMBL6545922 | 0.80 | MAPT (0.48) | MAPTABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL29118239 | 0.79 | ALDH1A1 (0.58) | MAPTABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6545840 | 0.76 | AKR1C4 (0.52) | MAPTALDH1A1LMNAMAPK1GAA | |
| SCHEMBL4847975 | 0.73 | MAPT (0.58) | MAPTALDH1A1LMNAMAPK1HDAC2 | |
| SCHEMBL5467266 | 0.73 | AKR1C3 (0.56) | ALDH1A1MCL1GAA | |
| SCHEMBL3950779 | 0.70 | GAA (0.45) | MAPTALDH1A1MCL1LMNAMAPK1 | |
| SCHEMBL14311224 | 0.70 | MEN1 (0.62) | MAPTABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL3486870 | 0.70 | MAPT (0.49) | MAPTALDH1A1LMNAPDK1PDK2 | |
| SCHEMBL8755784 | 0.69 | L3MBTL1 (0.59) | MAPTALDH1A1LMNATP53HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326788-B2 | Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-05 | — | — | US | disclosed |
| US-7326788-B2 | Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-05 | — | — | US | disclosed |
| CN-1867334-A | Quinolinone derivatives as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-22 | — | — | CN | disclosed |
| EP-1660087-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | disclosed |
| WO-2005009967-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | FLT3, ABL1, FES | MAPT 472/4885ABCC9 3241/4885ABCC8 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.